Related Experiment Video
Updated: Jun 20, 2026
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
Published on: February 4, 2014
Blinding in clozapine trials: a problem and a potential solution
Tamar Wohlfarth1, Don Linszen, Wim Van Den Brink
1Department of Psychiatry, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands.
Insights
A new study design addresses a methodological issue in antipsychotic drug trials. This approach maintains blinding and randomization while preventing underestimation of comparator drug efficacy, crucial for clozapine studies.
Area of Science:
- Psychiatry
- Clinical Trials
- Pharmacology
Background:
- Comparing clozapine efficacy with other antipsychotics in double-blind studies presents a methodological challenge.
- Mandatory blood testing for clozapine due to leucopenia/agranulocytosis risks necessitates similar testing in comparator groups to maintain blinding.
- This can lead to underestimation of treatment acceptability and efficacy for comparator drugs.
Purpose of the Study:
- To propose a novel study design to overcome the methodological problem in comparing clozapine with other antipsychotics.
- To preserve randomization and blinding while accurately assessing treatment efficacy and acceptability.
- To minimize the need for blood testing in comparator groups.
Main Methods:
- A thought experiment was conducted to explore solutions for the methodological problem.
- A special study design was developed involving initial randomization to distinct sub-studies.
- One sub-study includes clozapine and a comparator arm; the other includes only comparator arms.
Main Results:
- The proposed design maintains randomization and blinding.
- It prevents the underestimation of comparator treatment effects.
- Blood testing is restricted to a small subset of patients in the clozapine sub-study.
Conclusions:
- The proposed design offers a solution for comparing clozapine with other antipsychotics.
- It addresses similar methodological issues in double-blind studies requiring differential monitoring.
- Limitations of the design are discussed, highlighting its potential applicability to other drug monitoring scenarios (e.g., lithium).
Background:
A methodological problem arises when efficacy of clozapine is compared with other antipsychotic medication in double blind randomized studies. Due to the risk of leucopenia and agranulocytosis, patients in the clozapine condition need to have regular blood testing. The problem is that in order to maintain blinding, patients in the comparison conditions need to undergo blood testing as well and this can lead to underestimation of treatment acceptability and efficacy of the comparators.
Methods:
A thought experiment considering all possible solutions for the methodological problem.
Results:
We propose a special study design that preserves randomization and blinding while at the same time prevents underestimation of the effect in the comparator treatments. In addition, the necessity for blood testing is limited to only a small number of patients who receive comparative treatments. The design involves initial randomization to a sub-study including clozapine and a small comparator arm or to a sub-study that includes only comparator arms. Blood testing is only necessary in the first sub-study.
Discussion:
Limitations of the proposed design are discussed. It is noted that this study design may offer a solution to similar situations where blood testing or other types of monitoring (e.g. as with lithium) is required in one but not in all of the treatment arms of a double blind randomized study.
Related Concept Videos
01:11Blinding
02:07Blind Procedures
01:26Psychosis: Goals of Pharmacotherapy
01:28Drug Therapy
Antianxiety Medications
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...